Hangzhou Tigermed Consulting Co., Ltd. (Tigermed) released its unaudited 2026 third-quarter report, highlighting solid top-line expansion offset by sizeable investment-related losses.
Revenue Trends • July–September revenue rose 17.38% year-on-year to RMB 2.08 billion, lifting nine-month revenue to RMB 5.79 billion, up 15.23%. • Growth was driven by higher demand for clinical research services, as reflected in a 33.10% jump in contract liabilities to RMB 1.44 billion, signalling a healthy forward order book.
Profitability • Q3 net profit attributable to shareholders fell 77.85% to RMB 141.11 million. • For the first nine months, the company recorded a net loss attributable to shareholders of RMB 272.05 million versus a profit of RMB 1.02 billion a year earlier. • Stripping out extraordinary items, nine-month underlying net profit improved 38.08% to RMB 450.07 million, underscoring stable core operations. • The swing into loss was mainly driven by fair-value and disposal losses on non-current financial assets totalling RMB 597.0 million and an investment income decline of 93.34% to RMB 29.33 million.
Cash Flow and Balance Sheet • Operating cash flow edged up 4.29% to RMB 771.31 million. • Net cash used in investing activities reached RMB 84.85 million, a reversal from a RMB 493.71 million inflow a year earlier, reflecting lower redemptions of wealth-management products. • As of 30 September, total assets stood at RMB 27.99 billion, down 1.32% from year-end 2025, while owners’ equity decreased 6.31% to RMB 19.64 billion. • Long-term borrowings expanded 178.88% to RMB 1.42 billion, partially funding a share-repurchase programme that lifted treasury shares to RMB 1.12 billion.
Share Repurchase and Incentive Plan • By early October, Tigermed had repurchased 20.96 million A-shares (2.43% of total share capital) for RMB 824.34 million at prices between RMB 38.22 and RMB 42.78 per share. • Shareholders also approved a 2026 restricted-share incentive scheme; grants were executed on 9 October following board and shareholder authorisations.
Governance Update • The Zhejiang Securities Regulatory Bureau issued warning letters and administrative penalties to Chairman Ye Xiaoping and Executive Director Cao Xiaochun for historical disclosure lapses in A-share holdings. The board, excluding the two executives, assessed the matters and confirmed their continued suitability to serve as directors.
Key Financial Ratios (Nine Months) • Basic EPS: –RMB 0.32 (2025: RMB 1.19) • Weighted ROE: –1.33% (2025: 4.89%)
Outlook Considerations Revenue momentum and rising contract liabilities point to sustained operational demand, yet earnings visibility remains tied to the performance of financial investments and the pace of treasury-share purchases, which have increased leverage. Management’s focus will likely remain on stabilising bottom-line performance and integrating the new restricted-share incentive plan without further diluting equity.
Comments